Welcome to Awesome Blog Design perfect blog
Business, Healthcare

Legend Biotech announces initiation of rolling submission of Biologics License Application to U.S. FDA seeking approval of BCMA CAR-T therapy cilta-cel for the treatment of relapsed and/or refractory multiple myeloma

Legend Biotech also achieves fifth milestone payment under its collaboration agreement with Janssen in clinical development of cilta-cel SOMERSET, N.J.–(BUSINESS WIRE)–#LegendBiotech–Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies

Business, Healthcare

FDA grants priority review to Merck’s supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) plus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer

Application Based on Overall Survival and Progression-Free Survival Data Comparing KEYTRUDA Plus Chemotherapy to Chemotherapy Alone From Pivotal Phase 3 KEYNOTE-590 Trial KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S.